https://www.taihooncology.com/2024-11-08https://www.taihooncology.com/us/2024-02-23https://www.taihooncology.com/us/products/2023-06-19https://www.taihooncology.com/us/products/medical-information/2019-12-03https://www.taihooncology.com/us/privacy/2025-05-01https://www.taihooncology.com/us/terms/2019-11-18https://www.taihooncology.com/us/science/2024-08-29https://www.taihooncology.com/us/science/research-development/2019-11-18https://www.taihooncology.com/us/science/product-pipeline/2025-11-11https://www.taihooncology.com/us/science/product-pipeline/futibatinib-cholangiocarcinoma/2025-06-04https://www.taihooncology.com/us/science/product-pipeline/futibatinib-esophageal/2023-12-11https://www.taihooncology.com/us/science/product-pipeline/tas-120-urothelial-cancer/2023-12-11https://www.taihooncology.com/us/science/product-pipeline/2astx727-decitabine-and-cedazuridine/2025-08-15https://www.taihooncology.com/us/science/product-pipeline/2astx727-decitabine-and-cedazuridine-acute-myeloid-leukemia/2025-11-11https://www.taihooncology.com/us/science/product-pipeline/zipalertinib-1l/2023-12-13https://www.taihooncology.com/us/science/product-pipeline/zipalertinib-2l-1/2023-12-13https://www.taihooncology.com/us/science/product-pipeline/astx030-azacitidine-and-cedazuridine/2025-08-15https://www.taihooncology.com/us/science/product-pipeline/tas0612/2023-12-11https://www.taihooncology.com/us/science/product-pipeline/tas2940/2023-12-11https://www.taihooncology.com/us/science/product-pipeline/tas3351/2023-12-11https://www.taihooncology.com/us/science/investigator-initiated-trials/2024-11-12https://www.taihooncology.com/us/science/investigator-initiated-trials/trifluridine-and-tipiracil-ftdtpi/2024-11-12https://www.taihooncology.com/us/science/investigator-initiated-trials/decitabine-and-cedazuridine-dec-c/2024-11-12https://www.taihooncology.com/us/science/investigator-initiated-trials/futibatinib/2024-11-12https://www.taihooncology.com/us/science/investigator-initiated-trials/zipalertinib/2024-11-12https://www.taihooncology.com/us/science/expanded-access/2024-06-06https://www.taihooncology.com/us/science/partnering/2026-02-13https://www.taihooncology.com/us/careers/2025-09-15https://www.taihooncology.com/us/careers/corporate-culture/2023-06-19https://www.taihooncology.com/us/careers/employee-benefits/2022-12-05https://www.taihooncology.com/us/careers/job-postings/2025-09-15https://www.taihooncology.com/us/grants-donations/2025-11-05https://www.taihooncology.com/us/grants-donations/continuing-medical-education/2025-11-05https://www.taihooncology.com/us/grants-donations/charitable-contributions/2024-08-29https://www.taihooncology.com/us/grants-donations/coming-soon/2023-01-26https://www.taihooncology.com/us/about/2024-12-16https://www.taihooncology.com/us/about/leadership-team/2026-03-09https://www.taihooncology.com/us/about/social-responsibility/2025-07-21https://www.taihooncology.com/us/about/social-responsibility/toi-covid-19-support/2020-04-28https://www.taihooncology.com/us/contact/2025-12-05https://www.taihooncology.com/us/news/2019-11-18https://www.taihooncology.com/us/news/2019-06-06-pl-pm-us-0007-2019-toi-astex-commercialization/2019-12-05https://www.taihooncology.com/us/news/2019-06-03-lon-pm-us-1265-2019-asco-data-release/2019-12-05https://www.taihooncology.com/us/news/2019-03-14-nccn-awards-grants-investigators/2019-12-05https://www.taihooncology.com/us/news/2019-03-01-toi-pm-us-0197-ccam-2019/2019-12-05https://www.taihooncology.com/us/news/2019-02-25-lon-pm-us-1213-fda-approves-gastric/2019-12-05https://www.taihooncology.com/us/news/2019-01-17-lon-pm-us-1152-toi-servier-present-data-asco-gi/2019-12-05https://www.taihooncology.com/us/news/2018-10-25-lon-pm-us-1135-lonsurf-gastric-snda/2019-12-05https://www.taihooncology.com/us/news/2018-10-22-nccn-awarded-2mill-research/2019-09-30https://www.taihooncology.com/us/news/2018-10-21-lon-pm-us-1134-tags-esmo-2018-data-release/2019-12-05https://www.taihooncology.com/us/news/2018-09-28-taiho-oncology-presents-real-world-adherence-data-lonsurf/2019-12-05https://www.taihooncology.com/us/news/2018-06-21-lon-pm-us-1100-tags-esmo-gi-2018-data-release/2019-12-05https://www.taihooncology.com/us/news/2018-06-20-taiho-oncology-presents-data-key-investigational-compound-tas-120/2019-12-05https://www.taihooncology.com/us/news/2018-06-14-taiho-oncology-and-servier-present-data-lonsurf-esmo-2018/2019-12-05https://www.taihooncology.com/us/news/2018-06-07-taiho-oncology-eliminates-co-pays-many-patients-treated-lonsurf/2019-12-05https://www.taihooncology.com/us/news/2018-05-09-taiho-oncology-announces-positive-topline-results-pivotal-phase-3/2019-09-06https://www.taihooncology.com/us/news/2018-04-13-taiho-oncology-presents-data-lonsurf/2019-12-05https://www.taihooncology.com/us/news/2018-03-08-taiho-oncology-announces-support-awareness-research-initiatives/2019-12-05https://www.taihooncology.com/us/news/2018-01-20-taiho-oncology-and-servier-present-lonsurf-data-asco-2018-gastrointestinal-cancers-symposium/2019-12-05https://www.taihooncology.com/us/news/2018-01-19-otsuka-signs-statement-support-womens-empowerment-principles/2019-09-06https://www.taihooncology.com/us/news/2018-01-12-taiho-oncology-announces-multiple-lonsurf-presentations-asco-2018/2019-09-06https://www.taihooncology.com/us/news/2018-01-02-taiho_oncology_names_timothy_whitten_president/2019-12-05https://www.taihooncology.com/us/news/2017-10-20-health-canada-grants-priority-review-status/2019-12-05https://www.taihooncology.com/us/news/2017-10-04-taiho-pharmaceutical-participate-japan-healthcare-venture-summit-2017/2019-09-10https://www.taihooncology.com/us/news/2016-11-18-taiho-oncology-inc-announces-expansion-canada/2019-09-06https://www.taihooncology.com/us/news/2016-05-31-taiho-oncology-inc-multiple-presentations-asco-2016-annual-meeting/2019-12-05https://www.taihooncology.com/us/news/2015-09-26-taiho-oncology-inc-announces-comprehensive-access-support-program-lonsurf/2019-09-30https://www.taihooncology.com/us/news/2015-09-22-taiho-oncology-inc-announces-fda-approval-lonsurf-refractory-metastatic-colorectal-cancer/2019-12-05https://www.taihooncology.com/us/news/2015-02-23-taiho-oncology-inc-announces-tas-102-new-drug-application-refractory-metastatic-colorectal-cancer-accepted-review-fda/2019-09-30https://www.taihooncology.com/us/news/2014-12-22-taiho-oncology-completes-submission-tas-102-new-drug-application-us-food-and-drug-administration-treatment-refractory-metastatic-colorectal-cancer/2019-12-05https://www.taihooncology.com/us/news/2014-10-20-taiho-oncology-inc-receives-fda-fast-track-designation-tas-102-potential-treatment-refractory-metastatic-colorectal-cancer/2019-12-05https://www.taihooncology.com/us/news/2014-07-23-taiho-pharmaceutical-invests-us-30-million-remiges-biopharma-fund-lp-foster-early-biotech-start-ups/2019-09-30https://www.taihooncology.com/us/news/2014-06-28-taiho-oncology-inc-announces-results-tas-102-global-phase-iii-recourse-trial-refractory-metastatic-colorectal-cancer/2019-12-05https://www.taihooncology.com/us/news/2014-05-12-taiho-oncology-inc-marks-transition-commercial-entity-key-management-appointment/2019-12-05https://www.taihooncology.com/us/news/2019-10-10-lon-pm-us-1285-jama-oncology-data-press-release/2019-12-16https://www.taihooncology.com/us/news/2019-10-31-toi-pm-us-0218-gcam-2019/2019-12-16https://www.taihooncology.com/us/news/2020-01-25-lonsurf-tas120-data-release-asco-gi-2020/2020-01-25https://www.taihooncology.com/us/news/2020-01-27-nccnorp-taiho-futibatinib/2020-01-27https://www.taihooncology.com/us/news/2020-02-11-astex-press-release-astx727-nda-acceptance/2020-02-20https://www.taihooncology.com/us/news/2020-03-02-ccam-2020/2020-03-02https://www.taihooncology.com/us/news/2020-05-31-asco-2020-data-release/2020-06-01https://www.taihooncology.com/us/news/2020-06-04-aacr-curtain-raiser-release/2020-06-04https://www.taihooncology.com/us/news/2020-07-inqovi-approval/2020-07-07https://www.taihooncology.com/us/news/2020-07-dr_yoder_announcement/2020-07-15https://www.taihooncology.com/us/news/2020-07-23-nccnorp-taiho-futibatinib/2020-07-23https://www.taihooncology.com/us/news/2020-09-01-nccnorp-taiho-decitabine-cedazuridine/2020-09-01https://www.taihooncology.com/us/news/2020-09-08_astex_press_release_md_anderson_collaboration/2020-09-08https://www.taihooncology.com/us/news/2020-09-15_esmo_2020_curtain_release/2020-09-15https://www.taihooncology.com/us/news/2020-10-28_astex_press_release_nci_crada/2020-10-28https://www.taihooncology.com/us/news/2020-10-23_mds_world_awareness_day/2020-10-23https://www.taihooncology.com/us/news/2020-11-02_gastric_cancer_awareness_month_2020/2020-11-02https://www.taihooncology.com/us/news/2020-11-23_toi_inqovi_nccn_guidelines/2020-12-04https://www.taihooncology.com/us/news/2020-12-09_toi_european_expansion/2020-12-09https://www.taihooncology.com/us/news/2020-12-02_ash_2020_curtain_release/2020-12-02https://www.taihooncology.com/us/news/2021-01-12_asco_gi_2021_curtain_raiser_release/2021-01-12https://www.taihooncology.com/us/news/2021-02-04_toi_lonsurf_nccn_compendium/2021-02-04https://www.taihooncology.com/us/news/2021-03-01_toi_ccam_2021/2021-03-01https://www.taihooncology.com/us/news/2021-04-01_toi_tpc_futibatinib_btd/2021-04-01https://www.taihooncology.com/us/news/2021-04-02_aacr_2021_curtain_raiser_release/2021-04-02https://www.taihooncology.com/us/news/2021-04-11_aacr_2021_data_release/2021-04-11https://www.taihooncology.com/us/news/2021-04-14_nccnorp_taiho_decitabinecedazuridineprojects/2021-04-14https://www.taihooncology.com/us/news/2021-09-01_open_letter_from_taiho_oncology_on_blood_cancer_awareness_month/2021-09-01https://www.taihooncology.com/us/news/2021-09-13_toi_esmo_2021_curtain_raiser/2021-09-13https://www.taihooncology.com/us/news/2021-09-23_astex_press_release_astx727_mos_data_presented_at_mds_international_symposium/2021-09-23https://www.taihooncology.com/us/news/2021-11-01_stomach_cancer_awareness_month_press_release/2021-11-01https://www.taihooncology.com/us/news/2022-03-01_ccam_2022_press_release/2022-03-01https://www.taihooncology.com/us/news/2022-03-30_toi_futibatinib_fda_nda_acceptance/2022-03-30https://www.taihooncology.com/us/news/2022-05-12_cln-081_agreement/2022-05-12https://www.taihooncology.com/us/news/2022-06-03_asco_2022_press_release/2022-06-03https://www.taihooncology.com/us/news/2022-09-12_sunlight_pr_positive_curtain_raiser/2022-09-12https://www.taihooncology.com/us/news/2022-09_lytgobi_approval/2022-09-30https://www.taihooncology.com/us/news/2022-12-12_toi_astex_ash_2022_data/2022-12-12https://www.taihooncology.com/us/news/2023-01-17_sunlight_asco_gi/2023-01-17https://www.taihooncology.com/us/news/2023-01-18_toi_foenix-cca2_nejm_publication/2023-01-18https://www.taihooncology.com/us/news/2023-04-18_toi_snda_acceptance_lonsurf_combo/2023-04-18https://www.taihooncology.com/us/news/2023-05-03_toi_and_servier_sunlight_nejm/2023-05-03https://www.taihooncology.com/us/news/2023-08-03_zipalertnib_phase3/2023-08-03https://www.taihooncology.com/us/news/2023-08-02_lonsurf-bev_approval/2023-08-02https://www.taihooncology.com/us/news/2023-11-17_taiho_astex_ash_data_presentation/2023-11-17https://www.taihooncology.com/us/news/2023-12-10_ash_data_presentation_us_real_world_study/2023-12-10https://www.taihooncology.com/us/news/2024-01-23_taiho_oncology_ascertain_publication/2024-01-23https://www.taihooncology.com/us/news/2014_11_05_ash_curtain_raiser_2024/2024-11-05https://www.taihooncology.com/us/news/taiho-oncology-data-at-ash-annual-meeting-highlight-progress-in-oral-therapies-for-patients-with-blood-cancers/2025-01-28https://www.taihooncology.com/us/news/taiho-oncology-to-present-data-at-the-2025-asco-gastrointestinal-cancers-symposium/2025-01-28https://www.taihooncology.com/us/news/taiho-oncology-announces-decitabine-and-cedazuridine-to-be-included-in-nih-precision-medicine-trials/2025-01-28https://www.taihooncology.com/us/news/taiho-oncology-presents-real-world-findings-for-lonsurf-at-the-asco-gastrointestinal-cancers-symposium/2025-01-28https://www.taihooncology.com/us/news/taiho-pharmaceutical-taiho-oncology-and-cullinan-therapeutics-announce-primary-endpoint-met-in-phase-2b-trial-of-zipalertinib-in-patients-with-non-small-cell-lung-cancer-harboring-egfr-exon-20-insertion-mutations-who-have-received-prior-therapy/2025-01-28https://www.taihooncology.com/us/news/taiho-oncology-to-share-data-in-five-presentations-including-two-oral-presentations-at-the-2025-american-society-of-clinical-oncology-annual-meeting/2025-04-23https://www.taihooncology.com/us/news/taiho-oncology-presents-data-at-the-2025-american-society-of-clinical-oncology-annual-meeting/2025-06-05https://www.taihooncology.com/us/news/cullinan-therapeutics-taiho-pharmaceutical-and-taiho-oncology-to-present-positive-results-from-pivotal-phase-2b-rezilient1-trial-of-zipalertinib-at-asco-2025/2025-05-22https://www.taihooncology.com/us/news/taiho-oncology-and-cullinan-therapeutics-announce-pivotal-rezilient1-phase-12-data-published-in-the-journal-of-clinical-oncology/2025-06-01https://www.taihooncology.com/us/news/taiho-oncology-and-taiho-pharmaceutical-announce-us-fda-acceptance-of-supplemental-new-drug-application-for-inqovi-in-combination-with-venetoclax-to-treat-patients-with-acute-myeloid-leukemia/2025-07-09https://www.taihooncology.com/us/news/taiho-oncology-and-cullinan-therapeutics-announce-acceptance-of-abstracts-for-zipalertinib-at-the-iaslc-2025-world-conference-on-lung-cancer/2025-07-22https://www.taihooncology.com/us/news/taiho-oncology-announces-acceptance-of-abstract-for-zipalertinib-at-the-esmo-congress-2025/2025-11-13https://www.taihooncology.com/us/news/taiho-oncology-and-cullinan-therapeutics-present-data-on-zipalertinib-at-the-iaslc-2025-world-conference-on-lung-cancer/2025-09-09https://www.taihooncology.com/us/news/taiho-oncology-and-cullinan-therapeutics-present-data-on-zipalertinib-in-patients-with-nsclc-with-egfr-mutations-and-active-brain-metastases-at-the-esmo-congress-2025/2025-10-13https://www.taihooncology.com/us/news/taiho-oncology-announces-14-presentations-including-six-oral-presentations-at-the-67th-american-society-of-hematology-annual-meeting-and-exposition/2025-11-13https://www.taihooncology.com/us/news/taiho-oncology-taiho-pharmaceutical-and-cullinan-therapeutics-initiate-rolling-submission-of-new-drug-application-to-us-food-and-drug-administration-for-zipalertinib-for-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-e/2025-12-08https://www.taihooncology.com/us/news/taiho-oncology-presents-data-on-all-oral-regimens-azacitidine-and-cedazuridine-and-decitabine-and-cedazuridine-at-the-2025-american-society-of-hematology-annual-meeting-and-exposition/2025-12-08https://www.taihooncology.com/us/news/peter-melnyk-joins-taiho-oncology-as-president-chief-operating-officer/2026-01-20https://www.taihooncology.com/us/news/taiho-oncology-appoints-peter-melnyk-as-president-chief-executive-officer/2026-01-28https://www.taihooncology.com/us/authorized-distributors/2020-04-08https://www.taihooncology.com/us/worldofhope/2021-02-09https://www.taihooncology.com/us/inqovi-hcp-resources-downloads/2024-09-04